Rabbit Polyclonal CDK18 Antibody

The cyclin-dependent kinase 18 (CDK18), a member of the CDK family, plays roles in regulating cell cycle progression, transcription, and DNA damage response. It interacts with cyclins (e.g., cyclin E) to modulate phosphorylation events critical for cell division and gene expression. CDK18 is implicated in DNA repair pathways and has been linked to cancer development due to its potential dysregulation in tumorigenesis. CDK18-specific antibodies are essential tools for studying its expression, localization, and activity in cellular contexts. Researchers use these antibodies in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to investigate CDK18's involvement in diseases, particularly cancers (e.g., colorectal, breast, and ovarian). Some studies suggest CDK18 overexpression correlates with poor prognosis, while others highlight its context-dependent tumor-suppressive roles. Antibody validation, including knockout cell line controls, is crucial due to cross-reactivity risks with other CDKs. Commercial CDK18 antibodies vary in clonal specificity (monoclonal vs. polyclonal) and applications. Recent interest in CDK18 as a therapeutic target has spurred the development of inhibitors, though its functional complexity warrants further exploration. Reliable antibodies remain vital for elucidating CDK18's signaling networks (e.g., interactions with MAPK or PI3K/AKT pathways) and its potential as a biomarker or drug target.